The haemoglobinopathy community is constantly evolving. Here we share some highlights of the NHP, its network members and its stakeholders regarding advances in their improvement, harmonisation and equity goals and efforts.
The guidance provides good practice advice for medical examiners on recognising the impact of SCD in various contexts including deaths and coroner referrals.
First iteration of the mortality reporting pathway for haemoglobinopathies.
Following the stepping down of Professor Baba Inusa, Dr Kate Gardner has been appointed the new NHP Chair.
Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)
The guidance provides good practice advice for medical examiners on recognising the impact of SCD in various contexts including deaths and coroner referrals.
First iteration of the mortality reporting pathway for haemoglobinopathies.
The NHP activity report for 2023/2024 (published 21 November 2024) gives an overview of its core and partner-related activities.
Following the stepping down of Professor Baba Inusa, Dr Kate Gardner has been appointed the new NHP Chair.
The guidance provides good practice advice for medical examiners on recognising the impact of SCD in various contexts including deaths and coroner referrals.
The NHP activity report for 2023/2024 (published 21 November 2024) gives an overview of its core and partner-related activities.
Following the stepping down of Professor Baba Inusa, Dr Kate Gardner has been appointed the new NHP Chair.
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
Home
About
The MDT
Science & innovation
News & features
Events
Contact
The National Haemoglobinopathy Panel
Women’s and Children’s Academic Health - Kings College London
Becket House
1 Lambeth Palace Rd
London, SE1 7EU
